Amy Wang

发表

Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.

R. Hamatake, Suoming Zhang, S. Baker, 2012, Journal of medicinal chemistry.

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.

Z. Ni, Suoming Zhang, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.

R. Hamatake, Suoming Zhang, S. Baker, 2012, Bioorganic & medicinal chemistry letters.

In Vitro Characterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor

R. Hamatake, Z. Hong, J. Vamathevan, 2013, Antimicrobial Agents and Chemotherapy.

764 IN VITRO PROFILING OF GSK2336805, A POTENT AND SELECTIVE INHIBITOR OF HCV NS5A

R. Hamatake, J. Vamathevan, W. Kazmierski, 2011 .

The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro

R. Milner, A. Mcintosh, C. Goodman, 2004, In Vitro Cellular & Developmental Biology - Animal.

Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A

R. Hamatake, J. Vamathevan, W. Kazmierski, 2013, Antimicrobial Agents and Chemotherapy.

Running title: Preclinical characterization of GSK2336805

R. Hamatake, J. Vamathevan, W. Kazmierski, 2013 .

P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY

R. Hamatake, Z. Hong, R. Crosby, 2014 .